UA114907C2 - Гетероциклільні сполуки як інгібітори mek - Google Patents
Гетероциклільні сполуки як інгібітори mekInfo
- Publication number
- UA114907C2 UA114907C2 UAA201411014A UAA201411014A UA114907C2 UA 114907 C2 UA114907 C2 UA 114907C2 UA A201411014 A UAA201411014 A UA A201411014A UA A201411014 A UAA201411014 A UA A201411014A UA 114907 C2 UA114907 C2 UA 114907C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compounds
- mek inhibitors
- heterocyclyl compounds
- formula
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Abstract
Дане розкриття стосується гетероарильних сполук, таких як інгібітори МЕК. Ці сполуки включають гетероарильні сполуки формули І, їх фармацевтично прийнятні солі, комбінації з придатним лікарським препаратом та їх фармацевтичні композиції. Дане розкриття також стосується способів одержання цих сполук та їх застосування у способах лікування. Ці сполуки, розкриті у даному документі, характеризуються нижченаведеною формулою (І): EMBED ISISServer (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN288KO2012 | 2012-03-14 | ||
| PCT/IB2013/051908 WO2013136249A1 (en) | 2012-03-14 | 2013-03-11 | Heterocyclyl compounds as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA114907C2 true UA114907C2 (uk) | 2017-08-28 |
Family
ID=47997632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201411014A UA114907C2 (uk) | 2012-03-14 | 2013-03-11 | Гетероциклільні сполуки як інгібітори mek |
| UAA201411011A UA114906C2 (uk) | 2012-03-14 | 2013-03-11 | Гетероциклільні сполуки як інгібітори мек |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201411011A UA114906C2 (uk) | 2012-03-14 | 2013-03-11 | Гетероциклільні сполуки як інгібітори мек |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9573944B2 (uk) |
| EP (2) | EP2834236B1 (uk) |
| JP (3) | JP6093384B2 (uk) |
| KR (4) | KR102240101B1 (uk) |
| CN (4) | CN108383836B (uk) |
| AP (2) | AP3834A (uk) |
| AU (4) | AU2013234009B2 (uk) |
| BR (1) | BR112014022713B1 (uk) |
| CA (2) | CA2865164C (uk) |
| CL (2) | CL2014002412A1 (uk) |
| CO (2) | CO7170131A2 (uk) |
| CR (2) | CR20140463A (uk) |
| CU (2) | CU24272B1 (uk) |
| DK (2) | DK2834237T3 (uk) |
| DO (2) | DOP2014000203A (uk) |
| EA (2) | EA029768B1 (uk) |
| ES (2) | ES2684517T3 (uk) |
| GE (2) | GEP201706774B (uk) |
| GT (2) | GT201400195A (uk) |
| HK (2) | HK1202538A1 (uk) |
| IL (2) | IL234559A (uk) |
| IN (2) | IN2014MN01754A (uk) |
| MA (2) | MA37405A1 (uk) |
| MX (3) | MX355474B (uk) |
| MY (2) | MY174188A (uk) |
| NI (2) | NI201400107A (uk) |
| NZ (2) | NZ629432A (uk) |
| PE (2) | PE20141973A1 (uk) |
| PH (2) | PH12014502040B1 (uk) |
| PL (1) | PL2834237T3 (uk) |
| SG (2) | SG11201405007QA (uk) |
| TN (2) | TN2014000356A1 (uk) |
| TR (1) | TR201811976T4 (uk) |
| UA (2) | UA114907C2 (uk) |
| WO (2) | WO2013136249A1 (uk) |
| ZA (1) | ZA201406186B (uk) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2834236B1 (en) | 2012-03-14 | 2019-05-22 | Lupin Limited | Heterocyclyl compounds |
| LT3176170T (lt) | 2012-06-13 | 2019-04-25 | Incyte Holdings Corporation | Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AU2014253798C1 (en) | 2013-04-19 | 2019-02-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3061747B1 (en) | 2013-10-25 | 2021-04-07 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof |
| WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016035008A1 (en) * | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| JP7219218B2 (ja) | 2016-12-22 | 2023-02-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| PE20210163A1 (es) | 2017-12-21 | 2021-01-26 | Boehringer Ingelheim Int | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 |
| JP2021523121A (ja) | 2018-05-04 | 2021-09-02 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| KR20220024191A (ko) | 2019-06-19 | 2022-03-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암제 조합 요법 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220106106A (ko) * | 2019-07-30 | 2022-07-28 | 에드빈세 아베 | 뇌졸중 치료용 mek 억제제 |
| EP3797899A1 (de) | 2019-09-27 | 2021-03-31 | Primetals Technologies Austria GmbH | Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4157836A1 (en) | 2020-06-02 | 2023-04-05 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| WO2022214594A1 (en) | 2021-04-09 | 2022-10-13 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3215081A1 (en) * | 2021-04-16 | 2022-10-20 | Alfredo C. Castro | Mek inhibitors and uses thereof |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4441054A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441055A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118613485A (zh) | 2021-12-01 | 2024-09-06 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118591540A (zh) | 2021-12-01 | 2024-09-03 | 勃林格殷格翰国际有限公司 | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 |
| CN114573582B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用 |
| CN114456166B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114573581B (zh) * | 2022-03-30 | 2023-09-01 | 沈阳药科大学 | 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| US20250019385A1 (en) | 2023-05-30 | 2025-01-16 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| UA72612C2 (en) * | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
| CA2473026C (en) * | 2002-01-22 | 2011-05-03 | Warner-Lambert Company Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| CA2727841A1 (en) * | 2004-06-11 | 2005-12-22 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds |
| BRPI0925050A2 (pt) | 2009-04-21 | 2015-08-04 | Novartis Ag | Compostos heterocíclicos como inibidores de mek |
| EP2834236B1 (en) | 2012-03-14 | 2019-05-22 | Lupin Limited | Heterocyclyl compounds |
-
2013
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/en active Active
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/en active Active
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko not_active Expired - Fee Related
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko active Application Filing
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active IP Right Cessation
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active Active
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/en active Application Filing
- 2013-03-11 CA CA2865164A patent/CA2865164C/en active Active
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 CA CA2865167A patent/CA2865167C/en not_active Expired - Fee Related
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/en active Application Filing
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
-
2014
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041A1/en unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
-
2015
- 2015-03-25 HK HK15103051.3A patent/HK1202538A1/xx unknown
- 2015-07-09 HK HK15106571.7A patent/HK1206020A1/xx not_active IP Right Cessation
-
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
-
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
-
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA114907C2 (uk) | Гетероциклільні сполуки як інгібітори mek | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| IN2014DN09434A (uk) | ||
| EA201201680A1 (ru) | Морфолинопиримидины и их применение в терапии | |
| IN2015DN01156A (uk) | ||
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| IN2014MN02598A (uk) | ||
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| IN2015DN01119A (uk) | ||
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| EA201590364A1 (ru) | Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| EA201491878A8 (ru) | Замещенные ксантиновые производные | |
| UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao |